RLYB331
RLYB331 (KY1066) is a is a monoclonal antibody targeting Matriptase-2 (TMPRSS6). RLYB331 binds to the serine protease active site of matriptase-2, blocking protease activity to increase hepcidin expression. RLYB331 reduces iron overload, inhibits α-aggregates, reduces ROS, inhibits apoptosis, and enhances erythroid differentiation. RLYB331 ameliorates ineffective erythropoiesis in β-thalassemic mouse models. RLYB331 can be used for the research of β-thalassemia.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
RLYB331 (10 mg/kg; i.p.; single dose) increases hepcidin expression via enhanced Bmp/Smad signaling in healthy C57BL/6 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:β-thalassemic (Hbbth3/+ ) mice and wild-type C57BL/6N mice (8-week-old; male)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; once weekly; 8 weeks
-
Result:Increased liver Hamp mRNA by 2.24-fold.
Increased serum hepcidin levels compared to isotype control.
Reduced serum iron levels and restored liver iron content to normal WT ranges.
Decreased liver iron staining by Perl's Prussian blue.
Reduced the number of erythroid cells in spleen fractions III (polychromatic) and IV (orthochromatic cells/reticulocytes).
Increased the number of terminally differentiated RBCs (fraction V) in spleen.
Reduced reactive oxygen species (ROS) to near-normal levels in spleen.
Reduced the percentage of apoptotic (annexin V+) erythroid cells in spleen.
Increased the number of terminally differentiated RBCs (fraction V) in bone marrow.
Eliminated detectable membrane-associated α-globin aggregates in circulating RBCs.
Corrected reticulocytosis.
Significantly reduced splenomegaly.
Did not significantly increase hemoglobin levels, hematocrit, or RBC counts compared to isotype control.
-
Animal Model:C57BL/6[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Increased Bmp/Smad signaling.
Increased hepcidin expression.
TMPRSS6
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Synonyms
KY1066
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Wake M, et al. A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice. Blood Adv. 2024;8(8):1898-1907. [Content Brief]
[2]. Niu C, et al. Immunoregulation role of the erythroid cells. Front Immunol. 2024;15:1466669. Published 2024 Oct 15. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
RLYB331 Related Classifications
HY-P992451 Related Classifications
Powered by Bioz